This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durus Manager Gets Hard Time

Scott Sacane, the disgraced hedge fund manager who claimed to have mistakenly accumulated a controlling stake in a tiny biotech company, is going to jail.

A U.S. judge sentenced Sacane on Tuesday to three years in federal prison. Sacane pleaded guilty in December 2005 to charges that he manipulated shares of two small biotech companies, Esperion and Aksys, by failing to disclose that his hedge fund had purchased huge equity stakes in both companies.

Sacane's sentencing comes nearly four years after his hedge fund, once worth $500 million, belatedly disclosed that it had amassed a 77% ownership stake in Aksys, a dialysis machine manufacturer, and a 33% stake in Esperion, a drug manufacturer.

Sacane initially said the fund "inadvertently" became the biggest shareholder in both companies, and denied doing anything wrong. He never explained, however, why Durus continued to keep buying shares even after cutting agreements with Aksys and Esperion to halt the purchases.

Aksys was delisted from Nasdaq in December and recently fetched 9 cents a share on the over-the-counter bulletin board. Esperion was purchased in 2004 by Pfizer (PFE - Get Report).

Sacane's bizarre defense never seemed credible, and most on Wall Street believed he was trying to manipulate the stock price of the two companies in order to inflate his hedge fund's returns.

"This prosecution and the term of imprisonment imposed today should send a strong message to hedge fund managers," says Connecticut U.S. Attorney Kevin O'Connor.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AKSY $0.00 -99.90%
PFE $28.46 -0.35%
AAPL $94.23 -0.82%
FB $100.22 0.47%
GOOG $687.67 0.72%


Chart of I:DJI
DOW 15,904.67 -122.38 -0.76%
S&P 500 1,847.76 -5.68 -0.31%
NASDAQ 4,278.8980 -4.8550 -0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs